TEVA:NYE-Teva Pharmaceutical Industries Limited American Depositary Shares (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 13.6

Change

+0.14 (+1.04)%

Market Cap

USD 38.25B

Volume

0.01B

Analyst Target

USD 12.19
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Its products include Copaxone, Azilect and Provigil.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-14 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

-1.61 (-1.07%)

USD 72.21B
HLN Haleon plc

+0.01 (+0.10%)

USD 45.41B
TAK Takeda Pharmaceutical Co Ltd A..

+0.24 (+1.68%)

USD 43.84B
RDY Dr. Reddy’s Laboratories Ltd..

+0.07 (+0.53%)

USD 10.62B
ELAN Elanco Animal Health

-0.44 (-5.07%)

USD 4.28B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.04 (-0.55%)

USD 3.25B
BHC Bausch Health Companies Inc

+0.18 (+4.15%)

USD 1.60B
CPHI China Pharma Holdings Inc

+1.33 (+950.00%)

USD 4.61M
YCBD cbdMD Inc

-0.02 (-6.67%)

USD 1.96M
EBS Emergent Biosolutions Inc

+0.05 (+1.09%)

N/A

ETFs Containing TEVA

FLWR:SW 5.80 % 0.00 %

N/A

N/A
ALFI 0.00 % 0.88 %

N/A

N/A
EIS iShares MSCI Israel ETF 0.00 % 0.59 %

+0.41 (+0%)

N/A
GNRX 0.00 % 0.55 %

N/A

N/A
GWL 0.00 % 0.34 %

N/A

N/A
ISRPF iShares Public Limited Co.. 0.00 % 0.00 %

N/A

USD 2.22B
ISRL:LSE 0.00 % 0.00 %

N/A

N/A
TASE:LSE 0.00 % 0.00 %

N/A

N/A
IS3T:F iShares IV Public Limited.. 0.00 % 0.00 %

+0.45 (+0%)

N/A
IS3T:XETRA iShares MSCI World Size F.. 0.00 % 0.00 %

+0.69 (+0%)

N/A
ISRCF iShares V Public Limited .. 0.00 % 0.00 %

+0.07 (+0%)

N/A
ISRHF iShares V Public Limited .. 0.00 % 0.00 %

N/A

N/A
ISRUF iShares V Public Limited .. 0.00 % 0.00 %

N/A

N/A
ISRZF iShares II Public Limited.. 0.00 % 0.00 %

N/A

N/A
ISRIF 0.00 % 0.00 %

N/A

N/A
ISRVF iShares Public Limited Co.. 0.00 % 0.00 %

N/A

N/A
ISRWF iShares II Public Limited.. 0.00 % 0.00 %

N/A

N/A
ISRNF 0.00 % 0.00 %

N/A

N/A
ISRRF 0.00 % 0.00 %

N/A

N/A
FLWG:LSE 0.00 % 0.00 %

N/A

N/A
FLWR:LSE 0.00 % 0.00 %

N/A

N/A
BLUM:XETRA 0.00 % 0.00 %

N/A

N/A
BLUM:F 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -38.29% 29% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.29% 29% F 5% F
Trailing 12 Months  
Capital Gain 2.80% 64% D 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.80% 57% F 47% F
Trailing 5 Years  
Capital Gain 35.19% 85% B 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.19% 69% C- 39% F
Average Annual (5 Year Horizon)  
Capital Gain 13.09% 71% C- 74% C
Dividend Return 13.09% 71% C- 69% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 42.83% 43% F 21% F
Risk Adjusted Return 30.56% 71% C- 46% F
Market Capitalization 38.25B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.40 N/A N/A
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector